Vijay Pande, formerly the head of Andreessen Horowitz’s roughly $4 billion biotech practice, is now taking a more focused approach with his new AI-native firm, VZVC. Rather than spreading capital across dozens of annual bets, Pande is emphasizing smaller, more deliberate investments in areas where AI can meaningfully reshape biology and medicine.
The optimistic core of his thesis is that biology is becoming an engineering discipline. With AI systems increasingly able to model, predict, and design biological processes, researchers may be able to move beyond trial-and-error discovery toward more systematic development of therapies, diagnostics, and tools.
Open data as the catalyst
Pande also highlights a crucial ingredient for progress: open, shared datasets. In his view, medicine will benefit most when AI researchers and healthcare innovators can build on common foundations rather than locking valuable biological and clinical data inside isolated silos.
- Open datasets can improve reproducibility and collaboration.
- Shared resources may help smaller teams compete with larger incumbents.
- Better data access could accelerate AI-driven drug discovery and biomedical research.
While clinical trials remain costly and difficult, Pande’s perspective points to a hopeful path forward: AI, paired with more open scientific infrastructure, could make medicine faster, smarter, and more collaborative. It is not a single breakthrough announcement, but it reflects a growing conviction that AI’s biggest healthcare wins may come from rethinking how the whole system learns.